-
公开(公告)号：US10322108B2
公开(公告)日：2019-06-18
申请号：US15541137
申请日：2016-01-22
发明人： Hai Xue , Tao Zhao , Mi Young Cha , Maengsup Kim
IPC分类号： A61K31/404 , C07D209/10 , C07D209/08 , A61K31/03 , A61K31/192 , A61K31/196
摘要： Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a RORγ mediated disease. The compound has the structural formula (I).
-
公开(公告)号：US09840517B2
公开(公告)日：2017-12-12
申请号：US15022248
申请日：2014-09-18
发明人： Jinming Liu , Mi Young Cha , Gong Li , Zhanmei Li , Hongjuan Qiu , Maengsup Kim
IPC分类号： C07D495/04 , A61K31/519 , A61K31/53 , A61K31/5377 , C07D487/04 , C07D491/048 , A61K45/06 , C07D519/00
CPC分类号： C07D495/04 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D487/04 , C07D491/048 , C07D519/00 , A61K2300/00
摘要： The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).
-
公开(公告)号：US20210040193A1
公开(公告)日：2021-02-11
申请号：US16968677
申请日：2019-02-02
发明人： Yaping Yang , Nanmeng Song , Wenchu Xiao , Zhenlei Li , Lina Zhang , Mingyue Gu , Chunguang Zhan , Jiawang Liu , Maengsup Kim
摘要： An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.
-
公开(公告)号：US20160229865A1
公开(公告)日：2016-08-11
申请号：US15022248
申请日：2014-09-18
发明人： Jinming Liu , Mi Young Cha , Gong Li , Zhanmei Li , Hongjuan Qiu , Maengsup Kim
IPC分类号： C07D495/04 , A61K31/519 , A61K31/53 , C07D519/00 , C07D491/048 , C07D487/04 , A61K45/06 , A61K31/5377
CPC分类号： C07D495/04 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D487/04 , C07D491/048 , C07D519/00 , A61K2300/00
摘要： The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).
摘要翻译： 本发明涉及抑制Bruton酪氨酸激酶（BTK）和/或Janus激酶3（JAK3）的活性的化合物，该化合物的药物组合物，其药学应用，使用该化合物抑制活性的方法 BTK和/或JAK3，以及使用该化合物治疗和/或预防哺乳动物（特别是人）中的BTK和/或JAK3介导的疾病或病症的方法。 该化合物由结构式（I）表示。
-
公开(公告)号：US11498977B2
公开(公告)日：2022-11-15
申请号：US16337854
申请日：2017-09-28
发明人： Jiawang Liu , Nanmeng Song , Dongge Yang , Yaping Yang , Maengsup Kim
摘要： The present invention provides a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.
-
公开(公告)号：US11319378B2
公开(公告)日：2022-05-03
申请号：US16461646
申请日：2017-11-16
发明人： Jiawang Liu , Nanmeng Song , Yaping Yang , Maengsup Kim
摘要： Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.
-
公开(公告)号：US10988482B2
公开(公告)日：2021-04-27
申请号：US15751766
申请日：2015-08-13
发明人： Baoyu Xue , Runa Zheng , Mi Young Cha , Maengsup Kim
IPC分类号： C07D495/04 , C07D487/04 , C07D491/048 , A61K45/06
摘要： The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (particularly humans). The compound has a structural formula I.
-
公开(公告)号：US20170368028A1
公开(公告)日：2017-12-28
申请号：US15541137
申请日：2016-01-22
发明人： Hai Xue , Tao Zhao , Mi Young Cha , Maengsup Kim
IPC分类号： A61K31/404 , A61K31/196 , A61K31/03 , A61K31/192 , C07D209/10 , C07D209/08
CPC分类号： A61K31/404 , A61K31/03 , A61K31/192 , A61K31/196 , C07D209/08 , C07D209/10 , Y02A50/409
摘要： Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a RORγ mediated disease. The compound has the structural formula (I).
-
公开(公告)号：US20210230277A1
公开(公告)日：2021-07-29
申请号：US16769108
申请日：2018-12-01
发明人： Jiawang Liu , Yaping Yang , Nanmeng Song , Maengsup Kim
摘要： Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407 and 409.
-
公开(公告)号：US20200062775A1
公开(公告)日：2020-02-27
申请号：US15751766
申请日：2015-08-13
发明人： Baoyu Xue , Runa Zheng , Mi Young Cha , Maengsup Kim
IPC分类号： C07D495/04 , C07D487/04 , C07D491/048
摘要： The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (particularly humans). The compound has a structural formula I.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.019 秒)
